Anti-tumor necrosis factor (TNF) biologics such as infliximab, adalimumab, and certolizumab, are generally well-tolerated, however; they are expensive and may increase the risk of infections as well as melanoma skin cancer. This evidence concerns the gene TNF and skin cancer.